US$150 million invested to expand US pharmaceutical distribution network
DHL Supply Chain is investing millions of dollars to expand its pharmaceutical and medical device distribution network in the US.
List view / Grid view
DHL Supply Chain is investing millions of dollars to expand its pharmaceutical and medical device distribution network in the US.
The UK’s newest life sciences asset, Health Innovation Research Alliance Northern Ireland (HIRANI), has been launched at a BIO reception.
The global pharmaceutical intermediates market is likely to see year-on-year growth in 2019, by an estimated 3.6 percent rate.
New briefing documents provide policy recommendations to help the EU tackle high medicines prices brought about by market monopolies.
Member countries of WHO have agreed to support pricing transparency for medicines, vaccines and other health products.
Global active pharmaceutical ingredients market set to surpass US$274.9 billion by 2026.
Pharmaceutical manufacturers and wholesale distributors could start losing billions of dollars because of faulty barcode scans.
The National Institute of Allergy and Infectious Diseases (NIAID) has awarded TB Alliance a CETR grant for tuberculosis drug development.
A $100 million investment has been made to support long-term vaccine manufacturing capabilities in the US.
UK-based biotech companies raised £2.2billion from investors in 2018, an increase of 85 percent from the year before, a report has found...
NIAID has released a plan for research in the infectious disease TB in order to strengthen efforts and resolve to attack this disease...
Two years ago, Servier launched an ambitious programme of transformation to adapt to the new reality of the pharmaceutical industry. Olivier Laureau, CEO of Servier and President of the Fondation Internationale de Recherche Servier, explains the initiative and other achievements.
Niall Dickson responds to the commitment by the secretaries of state to seek a collaborative relationship with the EU in medicines regulation and supply...
NICE has approved adalimumab (Humira, AbbVie), etanercept (Enbrel, Pfizer) and ustekinumab (Stelara, Janssen) for treating plaque psoriasis in children...
Collaboration between the pharmaceutical industry, patients and health regulators will be a ‘game changer’ in delivering exciting new cell and gene therapies to treat conditions like cancer and vision loss.